Propranolol Hydrochloride and Hydrochlorothiazide

×

Overview

What is Propranolol Hydrochloride and Hydrochlorothiazide?

Propranolol hydrochloride and hydrochlorothiazide tablets, USP for oral administration combine two antihypertensive agents: propranolol hydrochloride, USP, a beta-adrenergic blocking agent, and hydrochlorothiazide, USP, a thiazide diuretic-antihypertensive. Propranolol hydrochloride and hydrochlorothiazide tablets, 40/25 contain 40 mg propranolol hydrochloride and 25 mg hydrochlorothiazide; propranolol hydrochloride and hydrochlorothiazide tablets, 80/25 contain 80 mg propranolol hydrochloride and 25 mg hydrochlorothiazide.

Propranolol hydrochloride is a synthetic beta-adrenergic receptor-blocking agent chemically described as 1-(Isopropylamino)-3-(1-naphthyloxy)-2-propanol hydrochloride. Its structural formula is:

Propranolol hydrochloride, USP is a stable, white, crystalline solid which is readily soluble in water and ethanol. Its molecular weight is 295.81.

Hydrochlorothiazide, USP is a white, or practically white, practically odorless, crystalline powder. It is slightly soluble in water; freely soluble in sodium hydroxide solution; sparingly soluble in methanol; insoluble in ether, chloroform, benzene, and dilute mineral acids. Its chemical name is: 6-Chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Its structural formula is:

Propranolol hydrochloride and hydrochlorothiazide tablets, 40 mg/25 mg and 80 mg/25 mg are for oral administration and contain the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose, pregelatinized corn starch and sodium lauryl sulfate.

What does Propranolol Hydrochloride and Hydrochlorothiazide look like?

What are the available doses of Propranolol Hydrochloride and Hydrochlorothiazide?

Sorry No records found.

What should I talk to my health care provider before I take Propranolol Hydrochloride and Hydrochlorothiazide?

Sorry No records found

How should I use Propranolol Hydrochloride and Hydrochlorothiazide?

Propranolol hydrochloride and hydrochlorothiazide tablets, USP are indicated in the management of hypertension.

This fixed combination is not indicated for initial therapy of hypertension. Hypertension requires therapy titrated to the individual patient. If the fixed combination represents the dosage so determined, its use may be more convenient in patient management.

The dosage must be determined by individual titration.

Hydrochlorothiazide can be given at doses of 12.5 to 50 mg per day when used alone. The initial dose of propranolol is 80 mg daily, and it may be increased gradually until optimal blood pressure control is achieved. The usual effective dose when used alone is 160 to 480 mg per day.

One propranolol hydrochloride and hydrochlorothiazide tablet twice daily can be used to administer up to 160 mg of propranolol and 50 mg of hydrochlorothiazide. For doses of propranolol greater than 160 mg the combination products are not appropriate, because their use would lead to an excessive dose of the thiazide component.

When necessary, another antihypertensive agent may be added gradually beginning with 50 percent of the usual recommended starting dose to avoid an excessive fall in blood pressure.

What interacts with Propranolol Hydrochloride and Hydrochlorothiazide?

Sorry No Records found

What are the warnings of Propranolol Hydrochloride and Hydrochlorothiazide?

Propranolol Hydrochloride

Hypersensitivity reactions, including anaphylactic/anaphylactoid reactions, have been associated with the administration of propranolol and hydrochlorothiazide (see ).

Array

Sympathetic stimulation is a vital component supporting circulatory function in congestive heart failure, and inhibition with beta-blockade always carries the potential hazard of further depressing myocardial contractility and precipitating cardiac failure. Propranolol acts selectively without abolishing the inotropic action of digitalis on the heart muscle (i.e., that of supporting the strength of myocardial contractions). In patients already receiving digitalis, the positive inotropic action of digitalis may be reduced by propranolol’s negative inotropic effect.

Array

Continued depression of the myocardium over a period of time can, in some cases, lead to cardiac failure. In rare instances, this has been observed during propranolol therapy. Therefore, at the first sign or symptom of impending cardiac failure, patients should be fully digitalized and/or given additional diuretic, and the response observed closely: a) if cardiac failure continues, despite adequate digitalization and diuretic therapy, propranolol therapy should be withdrawn (gradually, if possible); b) if tachyarrhythmia is being controlled, patients should be maintained on combined therapy and the patient closely followed until threat of cardiac failure is over.

Array

PATIENTS WITH BRONCHOSPASTIC DISEASES SHOULD, IN GENERAL, NOT RECEIVE BETA-BLOCKERS. Propranolol should be administered with caution since it may block bronchodilation produced by endogenous and exogenous catecholamine stimulation of beta-receptors.

Array

Chronically administered beta-blocking therapy should not be routinely withdrawn prior to major surgery, however the impaired ability of the heart to respond to reflex adrenergic stimuli may augment the risks of general anesthesia and surgical procedures.

Array

Hypersensitivity reactions, including anaphylactic/anaphylactoid reactions, have been associated with the administration of propranolol and hydrochlorothiazide (see ).

Array

Beta-blockade may mask certain clinical signs of hyperthyroidism. Therefore, abrupt withdrawal of propranolol may be followed by an exacerbation of symptoms of hyperthyroidism, including thyroid storm. Propranolol may change thyroid-function tests, increasing T and reverse T and decreasing T.

Array

Several cases have been reported in which, after propranolol, the tachycardia was replaced by a severe bradycardia requiring a demand pacemaker. In one case this resulted after an initial dose of 5 mg propranolol.

Array

Cutaneous reactions, including Stevens-Johnson Syndrome, toxic epidermal necrolysis, exfoliative dermatitis, erythema multiforme, and urticaria, have been reported with use of propranolol (see ).

Hydrochlorothiazide

Thiazides should be used with caution in severe renal disease. In patients with renal disease, thiazides may precipitate azotemia. In patients with impaired renal function, cumulative effects of the drug may develop.

Thiazides should also be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma.

Thiazides may add to or potentiate the action of other antihypertensive drugs. Potentiation occurs with ganglionic or peripheral adrenergic-blocking drugs.

Sensitivity reactions may occur in patients with a history of allergy or bronchial asthma. The possibility of exacerbation or activation of systemic lupus erythematosus has been reported.

Hydrochlorothiazide, a sulfonamide, can cause an idiosyncratic reaction, resulting in acute transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure glaucoma can lead to permanent vision loss. The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy.

What are the precautions of Propranolol Hydrochloride and Hydrochlorothiazide?

General

Array

Propranolol should be used with caution in patients with impaired hepatic or renal function. Propranolol hydrochloride and hydrochlorothiazide tablets are not indicated for the treatment of hypertensive emergencies.

Array

Information for Patients

Beta-adrenoreceptor blockade can cause reduction of intraocular pressure. Patients should be told that propranolol hydrochloride and hydrochlorothiazide may interfere with the glaucoma screening test. Withdrawal may lead to a return of increased intraocular pressure.

Laboratory Tests

Array

Elevated blood urea levels in patients with severe heart disease, elevated serum transaminase, alkaline phosphatase, lactate dehydrogenase.

Array

Periodic determination of serum electrolytes to detect possible electrolyte imbalance should be performed at appropriate intervals.

Drug/Drug Interactions

Array

Array

Drug/Laboratory Test Interactions

Thiazides may decrease serum PBI levels without signs of thyroid disturbance.

Thiazides should be discontinued before carrying out tests for parathyroid function (see ).

Carcinogenesis, Mutagenesis, Impairment of Fertility

Combinations of propranolol and hydrochlorothiazide have not been evaluated for carcinogenic or mutagenic potential or for potential to adversely affect fertility.

Array

In dietary administration studies in which mice and rats were treated with propranolol for up to 18 months at doses of up to 150 mg/kg/day, there was no evidence of drug-related tumorigenesis. In a study in which both male and female rats were exposed to propranolol in their diets at concentrations of up to 0.05%, from 60 days prior to mating and throughout pregnancy and lactation for two generations, there were no effects on fertility. Based on differing results from Ames Tests performed by different laboratories, there is equivocal evidence for a genotoxic effect of propranolol in bacteria ( strain TA 1538).

Array

Combinations of propranolol and hydrochlorothiazide have not been evaluated for carcinogenic or mutagenic potential or for potential to adversely affect fertility.

Pregnancy

Combinations of propranolol and hydrochlorothiazide have not been evaluated for effects on pregnancy in animals. Nor are there adequate and well controlled studies of propranolol, hydrochlorothiazide or the combination in pregnant women. Propranolol and hydrochlorothiazide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers

Array

Propranolol is excreted in human milk. Caution should be exercised when propranolol hydrochloride and hydrochlorothiazide is administered to a nursing woman.

Array

Thiazides appear in breast milk. If the use of the drug is deemed essential, the patient should stop nursing.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

Geriatric Use

Clinical studies of propranolol hydrochloride and hydrochlorothiazide did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.

In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

What are the side effects of Propranolol Hydrochloride and Hydrochlorothiazide?

The following adverse reactions have been observed, but there is not enough systematic collection of data to support an estimate of their frequency. Within each category, adverse reactions are listed in decreasing order of severity. Although many side effects are mild and transient, some require discontinuation of therapy.

Propranolol Hydrochloride

Hydrochlorothiazide

What should I look out for while using Propranolol Hydrochloride and Hydrochlorothiazide?

What might happen if I take too much Propranolol Hydrochloride and Hydrochlorothiazide?

The propranolol hydrochloride component may cause bradycardia, cardiac failure, hypotension, or bronchospasm. Propranolol is not significantly dialyzable.

The hydrochlorothiazide component can be expected to cause diuresis. Lethargy of varying degree may appear and may progress to coma within a few hours, with minimal depression of respiration and cardiovascular function, and in the absence of significant serum electrolyte changes or dehydration. The mechanism of central nervous system depression with thiazide overdosage is unknown. Gastrointestinal irritation and hypermotility can occur, temporary elevation of BUN has been reported, and serum electrolyte changes could occur, especially in patients with impairment of renal function.

The oral LD dosages in rats and mice for propranolol, hydrochlorothiazide and combined propranolol/hydrochlorothiazide (40/25, 80/25) are 364 to 533 mg/kg, greater than 2750 to 5000 mg/kg, and 538 to 845 mg/kg, respectively.

How should I store and handle Propranolol Hydrochloride and Hydrochlorothiazide?

Propranolol Hydrochloride and Hydrochlorothiazide Tablets, USP are available in the following combinations:The 40 mg/25 mg tablets contain 40 mg of propranolol hydrochloride, USP and 25 mg of hydrochlorothiazide, USP. Each white round scored tablet is debossed with over on one side of the tablet and scored on the other side. They are available as follows:NDC 0378-0731-01bottles of 100 tabletsThe 80 mg/25 mg tablets contain 80 mg of propranolol hydrochloride, USP and 25 mg of hydrochlorothiazide, USP. Each white round scored tablet is debossed with over on one side of the tablet and scored on the other side. They are available as follows:NDC 0378-0347-01bottles of 100 tabletsStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]Protect from moisture, freezing, and excessive heat.Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.Mylan Pharmaceuticals Inc.Morgantown, WV 26505 U.S.A.REVISED JUNE 2015PRAN/HCTZ:R20Propranolol Hydrochloride and Hydrochlorothiazide Tablets, USP are available in the following combinations:The 40 mg/25 mg tablets contain 40 mg of propranolol hydrochloride, USP and 25 mg of hydrochlorothiazide, USP. Each white round scored tablet is debossed with over on one side of the tablet and scored on the other side. They are available as follows:NDC 0378-0731-01bottles of 100 tabletsThe 80 mg/25 mg tablets contain 80 mg of propranolol hydrochloride, USP and 25 mg of hydrochlorothiazide, USP. Each white round scored tablet is debossed with over on one side of the tablet and scored on the other side. They are available as follows:NDC 0378-0347-01bottles of 100 tabletsStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]Protect from moisture, freezing, and excessive heat.Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.Mylan Pharmaceuticals Inc.Morgantown, WV 26505 U.S.A.REVISED JUNE 2015PRAN/HCTZ:R20Propranolol Hydrochloride and Hydrochlorothiazide Tablets, USP are available in the following combinations:The 40 mg/25 mg tablets contain 40 mg of propranolol hydrochloride, USP and 25 mg of hydrochlorothiazide, USP. Each white round scored tablet is debossed with over on one side of the tablet and scored on the other side. They are available as follows:NDC 0378-0731-01bottles of 100 tabletsThe 80 mg/25 mg tablets contain 80 mg of propranolol hydrochloride, USP and 25 mg of hydrochlorothiazide, USP. Each white round scored tablet is debossed with over on one side of the tablet and scored on the other side. They are available as follows:NDC 0378-0347-01bottles of 100 tabletsStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]Protect from moisture, freezing, and excessive heat.Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.Mylan Pharmaceuticals Inc.Morgantown, WV 26505 U.S.A.REVISED JUNE 2015PRAN/HCTZ:R20Propranolol Hydrochloride and Hydrochlorothiazide Tablets, USP are available in the following combinations:The 40 mg/25 mg tablets contain 40 mg of propranolol hydrochloride, USP and 25 mg of hydrochlorothiazide, USP. Each white round scored tablet is debossed with over on one side of the tablet and scored on the other side. They are available as follows:NDC 0378-0731-01bottles of 100 tabletsThe 80 mg/25 mg tablets contain 80 mg of propranolol hydrochloride, USP and 25 mg of hydrochlorothiazide, USP. Each white round scored tablet is debossed with over on one side of the tablet and scored on the other side. They are available as follows:NDC 0378-0347-01bottles of 100 tabletsStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]Protect from moisture, freezing, and excessive heat.Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.Mylan Pharmaceuticals Inc.Morgantown, WV 26505 U.S.A.REVISED JUNE 2015PRAN/HCTZ:R20Propranolol Hydrochloride and Hydrochlorothiazide Tablets, USP are available in the following combinations:The 40 mg/25 mg tablets contain 40 mg of propranolol hydrochloride, USP and 25 mg of hydrochlorothiazide, USP. Each white round scored tablet is debossed with over on one side of the tablet and scored on the other side. They are available as follows:NDC 0378-0731-01bottles of 100 tabletsThe 80 mg/25 mg tablets contain 80 mg of propranolol hydrochloride, USP and 25 mg of hydrochlorothiazide, USP. Each white round scored tablet is debossed with over on one side of the tablet and scored on the other side. They are available as follows:NDC 0378-0347-01bottles of 100 tabletsStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]Protect from moisture, freezing, and excessive heat.Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.Mylan Pharmaceuticals Inc.Morgantown, WV 26505 U.S.A.REVISED JUNE 2015PRAN/HCTZ:R20Propranolol Hydrochloride and Hydrochlorothiazide Tablets, USP are available in the following combinations:The 40 mg/25 mg tablets contain 40 mg of propranolol hydrochloride, USP and 25 mg of hydrochlorothiazide, USP. Each white round scored tablet is debossed with over on one side of the tablet and scored on the other side. They are available as follows:NDC 0378-0731-01bottles of 100 tabletsThe 80 mg/25 mg tablets contain 80 mg of propranolol hydrochloride, USP and 25 mg of hydrochlorothiazide, USP. Each white round scored tablet is debossed with over on one side of the tablet and scored on the other side. They are available as follows:NDC 0378-0347-01bottles of 100 tabletsStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]Protect from moisture, freezing, and excessive heat.Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.Mylan Pharmaceuticals Inc.Morgantown, WV 26505 U.S.A.REVISED JUNE 2015PRAN/HCTZ:R20Propranolol Hydrochloride and Hydrochlorothiazide Tablets, USP are available in the following combinations:The 40 mg/25 mg tablets contain 40 mg of propranolol hydrochloride, USP and 25 mg of hydrochlorothiazide, USP. Each white round scored tablet is debossed with over on one side of the tablet and scored on the other side. They are available as follows:NDC 0378-0731-01bottles of 100 tabletsThe 80 mg/25 mg tablets contain 80 mg of propranolol hydrochloride, USP and 25 mg of hydrochlorothiazide, USP. Each white round scored tablet is debossed with over on one side of the tablet and scored on the other side. They are available as follows:NDC 0378-0347-01bottles of 100 tabletsStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]Protect from moisture, freezing, and excessive heat.Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.Mylan Pharmaceuticals Inc.Morgantown, WV 26505 U.S.A.REVISED JUNE 2015PRAN/HCTZ:R20Propranolol Hydrochloride and Hydrochlorothiazide Tablets, USP are available in the following combinations:The 40 mg/25 mg tablets contain 40 mg of propranolol hydrochloride, USP and 25 mg of hydrochlorothiazide, USP. Each white round scored tablet is debossed with over on one side of the tablet and scored on the other side. They are available as follows:NDC 0378-0731-01bottles of 100 tabletsThe 80 mg/25 mg tablets contain 80 mg of propranolol hydrochloride, USP and 25 mg of hydrochlorothiazide, USP. Each white round scored tablet is debossed with over on one side of the tablet and scored on the other side. They are available as follows:NDC 0378-0347-01bottles of 100 tabletsStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]Protect from moisture, freezing, and excessive heat.Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.Mylan Pharmaceuticals Inc.Morgantown, WV 26505 U.S.A.REVISED JUNE 2015PRAN/HCTZ:R20Propranolol Hydrochloride and Hydrochlorothiazide Tablets, USP are available in the following combinations:The 40 mg/25 mg tablets contain 40 mg of propranolol hydrochloride, USP and 25 mg of hydrochlorothiazide, USP. Each white round scored tablet is debossed with over on one side of the tablet and scored on the other side. They are available as follows:NDC 0378-0731-01bottles of 100 tabletsThe 80 mg/25 mg tablets contain 80 mg of propranolol hydrochloride, USP and 25 mg of hydrochlorothiazide, USP. Each white round scored tablet is debossed with over on one side of the tablet and scored on the other side. They are available as follows:NDC 0378-0347-01bottles of 100 tabletsStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]Protect from moisture, freezing, and excessive heat.Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.Mylan Pharmaceuticals Inc.Morgantown, WV 26505 U.S.A.REVISED JUNE 2015PRAN/HCTZ:R20Propranolol Hydrochloride and Hydrochlorothiazide Tablets, USP are available in the following combinations:The 40 mg/25 mg tablets contain 40 mg of propranolol hydrochloride, USP and 25 mg of hydrochlorothiazide, USP. Each white round scored tablet is debossed with over on one side of the tablet and scored on the other side. They are available as follows:NDC 0378-0731-01bottles of 100 tabletsThe 80 mg/25 mg tablets contain 80 mg of propranolol hydrochloride, USP and 25 mg of hydrochlorothiazide, USP. Each white round scored tablet is debossed with over on one side of the tablet and scored on the other side. They are available as follows:NDC 0378-0347-01bottles of 100 tabletsStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]Protect from moisture, freezing, and excessive heat.Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.Mylan Pharmaceuticals Inc.Morgantown, WV 26505 U.S.A.REVISED JUNE 2015PRAN/HCTZ:R20

×

Clinical Information

Chemical Structure

No Image found

Clinical Pharmacology

Propranolol hydrochloride is a nonselective beta-adrenergic receptor blocking agent possessing no other autonomic nervous system activity. It specifically competes with beta-adrenergic receptor stimulating agents for available receptor sites. When access to beta-receptor sites is blocked by propranolol, the chronotropic, inotropic, and vasodilator responses to beta-adrenergic stimulation are decreased proportionately.

Propranolol is almost completely absorbed from the gastrointestinal tract, but a portion is immediately metabolized by the liver on its first pass through the portal circulation.

Peak effect occurs in one to one-and-one-half hours. The biologic half-life is approximately 4 hours. Propranolol is not significantly dialyzable. There is no simple correlation between dose or plasma level and therapeutic effect, and the dose-sensitivity range, as observed in clinical practice, is wide. The principal reason for this is that sympathetic tone varies widely between individuals. Since there is no reliable test to estimate sympathetic tone or to determine whether total beta-blockade has been achieved, proper dosage requires titration.

The mechanism of the antihypertensive effect of propranolol has not been established. Among the factors that may be involved in contributing to the antihypertensive action are (1) decreased cardiac output, (2) inhibition of renin release by the kidneys, and (3) diminution of tonic sympathetic nerve outflow from vasomotor centers in the brain. Although total peripheral resistance may increase initially, it readjusts to, or below, the pretreatment level with chronic use. Effects on plasma volume appear to be minor and somewhat variable. Propranolol has been shown to cause a small increase in serum potassium concentration when used in the treatment of hypertensive patients. Propranolol hydrochloride decreases heart rate, cardiac output, and blood pressure.

Beta-receptor blockade can be useful in conditions in which, because of pathologic or functional changes, sympathetic activity is detrimental to the patient. But there are also situations in which sympathetic stimulation is vital. For example, in patients with severely damaged hearts, adequate ventricular function is maintained by virtue of sympathetic drive, which should be preserved. In the presence of AV block greater than first degree, beta-blockade may prevent the necessary facilitating effect of sympathetic activity on conduction. Beta-blockade results in bronchial constriction by interfering with adrenergic bronchodilator activity, which should be preserved in patients subject to bronchospasm.

The proper objective of beta-blockade therapy is to decrease adverse sympathetic stimulation, but not to the degree that may impair necessary sympathetic support.

Non-Clinical Toxicology

The following adverse reactions have been observed, but there is not enough systematic collection of data to support an estimate of their frequency. Within each category, adverse reactions are listed in decreasing order of severity. Although many side effects are mild and transient, some require discontinuation of therapy.

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72

×

Tips

×

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).

Disclaimer: